CHARLES F LEVENBACK to Cystadenocarcinoma, Serous
This is a "connection" page, showing publications CHARLES F LEVENBACK has written about Cystadenocarcinoma, Serous.
Connection Strength
0.192
-
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012 Jun; 125(3):640-5.
Score: 0.073
-
Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller. Int J Gynecol Cancer. 2010 Apr; 20(3):353-7.
Score: 0.064
-
Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer. 1998 Nov 15; 83(10):2157-63.
Score: 0.029
-
What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies? J Chemother. 2009 Nov; 21(5):566-72.
Score: 0.016
-
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol. 2003 Jan 15; 21(2):291-7.
Score: 0.010